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Hepatoerythropoietic porphyria is a severe cutaneous 
porphyria caused by deficiency of uroporphyrinogen 
decarboxylase and is considered to be the homozy-
gous form of familial (type II) porphyria cutanea 
tarda. To elucidate further the relation between these 
conditions, we studied five Spanish families with hepa-
t o erythropoietic porphyria and nine unrelated Spanish 
patients with familial porphyria cutanea tarda. Immu-
noreactive and catalytic uroporphyrinogen decarboxyl-
ase was decreased by greater than 95% in the five 
patients with hepatoerythropoietic porphyria. Hepa-
tic uroporphyrinogen decarboxylase activity was de-
creased to 22% of normal. Four patients were homozy-
gous for a mutation (G281E) originally identified in a 
H epatoerythropoietic porphyria (HEP) is a rare form of cutaneou s p o rphyria in which the onset of skin lesions in early childhood is associated with severe deficiency of uroporphyrinoge n d ecarboxylase (UROD) [1 ,2]. Because both parents of som e 
patients with HEP have been shown to have half-normal con cen-
trations ofUROD in their erythrocytes and are therefore bioc hem-
ically indistinguish able from asymptomatic carriers of the autosom al 
dominant (type II) form of familial porphyria cutanea tarda (peT), 
it has been suggested that HEP is the homozygou s form of familial 
peT [3] . However, clinically overt peT h as not yet b een reported 
in any fam ily w ith HEP. In addition, recent bioch emical and 
molecular genetic investigations h ave shown that each conditio n is 
h eterogeneous and h ave fa iled to identify an y mutations common 
to both [4,5]. 
Twenty-three patients with HEP from 19 fa milies h ave been 
described [4-9]. Five of these fam ilies are Spanish; patients from 
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Tunisian family; the fifth patient was a compound 
heterozygote for this mutation. The calculated carrier 
frequency for G281E in Spain is one in 1800. None of the 
nine familial porphyria cutanea tarda patients carried 
the G281E mutation. However, one G281E heterozy-
gote in a family with hepatoerythropoietic porphyria 
had overt porphyria cutanea tarda. These findings sug-
gest that the G281E mutation is functionally less severe 
than erythrocyte measurements indicate, that its clini-
cal penetrance is very low in heterozygotes, and that, 
for this particular mutation, hepatoerythropoietic por-
phyria is the homozygous form of familial porphyria 
cutanea tarda. Key lVord: i1tl,erita1tce. ] Itrvest Derlllatol 
104:500-502, 1995 
three of them are homozygous for a mutation (G281 E) , originally 
described in a Tunisian fami ly, that substitutes g lutamic acid for 
g lycine at amino acid 281 of the UROD molecul e [7 ,10,11]. N o 
other muta tio n has yet been found in more than one family with 
HEP [4,5]. 
In this report, w e describe a biochemi ca l and genetic inves tiga-
tion of HEP and familial peT in Spain. W e show that, although 
overt peT does occur in he terozygotes for th e G281 E mutation, 
this mutation appears to be an uncommon ca use of familial peT in 
Spa in . 
MATERJALS AND METHODS 
Patients Blood was obtain ed from five patients with HEP (patients 1-5) . 
from the parents and paternal uncle of patient 1, and from nine unrelated 
patients wi th clinica lly overt familial PCT. Pati ent 1 is a girl who presented 
with post-traumatic blisters on the face and dorsa of the hands at the age of 
11 months in 1984. Biochemical investigation showed an increased urinary 
porphyrin excretion (840 ILg/24 h; 45%, uroporphyrin. 26°;', heptacarbo"'YI.i c 
porphyrin) , an increased concentra tion o f isocoproporphyrin in the feces 
(total porphyrin 103 ILg/g dry weight; 22°;', isocoproporphYI'in), and an 
increased erythrocyte protoporphyrin concentration (270 ILg/ dl). Her par-
ents were unrelated and had no c1jnical manifestations. Analysis of their 
blood, urine, and feces showed no abnormalities. A 33-year-old paternal 
uncle had had post-traumatic blisters on the dorsa of his hands, fac ial 
hyperpigmenwtion, and hypertrichosis since the age of 23. His urinary 
porphyrin excretion was increased (3002 ILg124 h; 49% uropo rphyrin, 32'X, 
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heptacarbo"J'li c porphy,;n), and isocoproporphyrin was 3 1 % of the total 
feca l porphyrin . Pa tien t 1 was included as case 13 in a series of patients with 
HE]> [1 2] but was described erro neously as a boy. 
C linica l details of the o ther patients with HEP ha ve been published: 
patien t 2 [1 3] , patient 3 [14], patient 4 [1 5], and patient 5 [6,11]. T he nine 
unre lated patients with fam i.!ia'! PCT had a m ean eryt.1uocyte UROD 
concen tration of 65 ng/ mg hemoglo bin , with a range of 49-77 ng/m g 
(normal subjects: mean 120 ng/ mg, range 73-164 ng/mg; n = 40); 
au tosomal dominant inhe ritan ce o f UROD de ficiency was confirmed by 
family studies [1 6]. A needle bio psy sample of liver was obtained from 
patie n t 5 during investigation of liver dysfunction; histopatholog ic exami-
natio n showed mild portal lymphocytic infiltration without fatty degener-
atio n o r siderosis. 
Biocben1 ical Methods Blood was anticoagulated with ethylenediamine 
te traacetic acid . Immuno reactive and catalytically active UROD in hem o-
lyzed whole blood and liver homogena tes was m easured as described 
prev io usly [1 7]. T he detection limit for immunoreactive UROD in hem o-
lyzed w ho le blood d iluted with phosphate-buffered saline was approxi-
m ately equivalent to an initial concentration of 2 ng/m g he moglobin in 
undiluted bloo d. Titrations with solid- phase antibody to UROD were 
carri ed o ut as described previously for m o use liver homogenates [1 8]. 
DNA Analysis DNA was isolated from whole blood, and sections of the 
UROD gene were amplified by the polymerase chain reaction using 
amplimers complem entary to sequences in exons 8 and 9 (sense: 5'-
A TCA TCTTTGCTAAGGA TGGGCA TITIGCC-3'; antisense: 5' -CTG-
CAATGTCACCGTCTICCCCACACACTC-3') and introns 5 .lI1d 6 
(sense: 5 ' -TCAGTCTGGCTTCTGTGACACCAT -3 '; antisense: 5 ' -TCT-
TGCTTCTGGTCCTTACAGACC-3'). PC R was perform ed for 30 cycles 
(denaturatio n: 94°C, 1 minu te; annealing: 60°C, 1 minu te; extension: 72°C , 
1.4 minutes) in a reactio n volume of 50 ILl (10 mM T ri s H C l pH 9.0, 50 mM 
KCl, 0. 1 % Triton X-1 00,1.5 111M MgCI2 , 200 mM dNT P, 50 pmol of each 
amplimer, and approximately 0 .5 ILg target DNA) . Amplifi ed D N A was 
examined for mu tations by dot blot hybridization to allele-specific o ligo-
nucleotides [7,19,20]. 
R ESULTS 
Erythrocyte UROD activity was decreased by greater than 95% in 
all fiv e patients with HEP (Table I). No immunoreactive UROD 
was detected by electroimmunoassay in hem olysates from these 
patients (Table I) . H emolysates £i'om three patients were titrated 
with solid-phase antibody. There was some uptake of catalytically 
active enzym e onto solid-phase antibody, but this was less than in 
control hemolysates diluted to the sam e UROD activity, suggestin g 
that the re is only partial cross-reactivi ty between the nonnal and 
mutant forms of UROD (data not shown). 
In contrast to e rythrocytes, UROD activity in the liver £i:om 
patient 5 w as decreased to only 22% of normal, and immunoreac-
tive enzyme was readily detectable (Table I). 
Analysis of amplified genomic DNA by hybridization w ith 
alle le-specifi c o ligonucleotides showed that four of the five patients 
with HEP w ere homozygous for the G281E mutation , as reported 
previously for patients 2, 4 [7] , and 5 [11], whereas one patient 
(patient 3) was a compound heterozygote (Table I) . T h e muta tion 
at the other aIle le in patient 3 was not identified, although large 
deletions [4] and two point mutations (E167K and an exon-6 splice 
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defect) [19, 20], which are known to markedly decrease the con-
centration of UROD in erythrocytes, were excluded . 
Figure 1 shows that the parents of patient 1 and her paternal 
uncle, who had overt PCT, were heterozygous for the G281E 
mutation . None of the nine unrelated patients with type II PCT 
were heterozygous for the G281E, E167K, or exon-6 splice-
defective mutations . 
DISCUSSION 
Our results show that HEP in Spain is genetically homogeneous. 
Nine of the ten UltOD-deficient chromosomes carried the G281E 
mutation . In contrast, D NA, enzymatic, and immunochemical 
studies have indicated that most of the 14 fu milies reported from 
outside Spain are likely to have different mutations [2,4,5 ,7] . The 
parents of only one of the Spanish cases (patient 5) are consanguin-
eous, and the families come from widely difl:e rent regions of Spain 
a.nd do not appear to be related. It thus seem s likely that the 
mutation o riginated in , or entered, Spain m an y years ago and h as 
now become distributed throughout the country. Assuming that the 
mutation is at equilibrium in the Spanish population, the calculated 
heterozygote frequ ency is about one in 1800, far higher than the 
prevalence of overt fa milial PCT. A previous study failed to find 
this mutation in 13 patients w ith fami lial PCT who cam e from 
outside Spa.in [7]. Here we report a similar finding for nin e Spanish 
patients with this form of PCT. However, we also show that 
heterozygosity for the G281E mutation can be associated with 
clinically overt PCT (Fig 1). In view of tillS finding and the wide 
95% confidence interval (0% to 30%) for our small sample, it seems 
probable that had we examined a larger number of unrelated 
Spatllsh patients with fami !ial (type II) PCT, we would have found 
som e who w ere heterozygous for this mutation. 
Table I shows that the functional effect of the G281E mutation 
on UROD activity is less marked in the liver, w lllch is the site of 
overproduction of porphyrins in HEP, tllal1 in erythrocytes. UROD 
activity in the liver lies in the range previously reported for 
clinica lly active PCT [17]. Studies of the tum over of the mutan t 
enzym e in liver and erythroid cells are required to explain the 
discrepancy between activities in these tissues . O ur results also 
suggest that the G281 E mutation may impair immunoreactivity to a 
greater extent than catalytic activity; another UROD mutation 
with a selective effect on immunoreactivity has been described [5]. 
Our resul ts clarify further the relation between HEP, familial 
PCT, and particular UROD mutations [5] . Homozygosity for the 
G281E mutation causes HE P; he terozygotes may develop clinically 
overt fam ilia l PCT. T hus, for this mutation, HEP is the homozy-
gous form of familial PCT. but th e relation is obscured by tile very 
low clinical penetran ce of the mutation in heterozygotes. Mutations 
that have a more severe functional effect, e.g., deletions [4] or 
splice-defectiv e mutations [20] that abolish activity, will be incom-
patibl e with life in the homozygous state and therefore w iIl only 
cause H EP w hen combined w ith a milder mutation in a compo und 
heterozygote [4], but may be expected to produce overt fa milial 
Table I. C0111.parison ofUROD Activity, Concentration, and Genotype in Five Patients with HEP" 
2 
3 
4 
5 
Patient 
Contro ls (n = 8) 
5 
Con tro ls (n = '16) 
Tissue 
Erythro cytes 
Erythrocytes 
Erytllrocytes 
Erythrocy tes 
Erytluocytcs 
Eryt.1uocytcs 
Liver 
Erythrocytes 
UROD Activity 
(pl1lol / min / mg) 
0.8 
0.5 
0.4 
0.5 
0.6 
21 .8 (1 9.3-24 .3) 
2.9 
13.1 (9 .1-18.2) 
Genotype 
UROD Concen tration Activity/Mass R atio UROD 
(ng/m g) (nm ollmin / m g) Alleles 
< 2 > 300 G28 1 E/G28 1 E 
< 2 > 300 G281 E/ G281E 
< 2 > 300 G28 1E/? 
< 2 > 300 G281 E/G281E 
< 2 > 300 G28 1E/ G281E 
129 (10 1- 151) 169 (160-200) 
16 18 1 
.125 (86-172) 109 (74 -155) 
II Activities and concentrations ill erythrocytes :,rc expressed pe r mg of hemoglobin . and in li ver. pCI' mg of pro te in. Data for U R OD ill the li ver fro l11 cOll trol subject!' is fr0111 
reference p 5]. 
